Home > NewsRelease > Dr. Jonathan G. Stine- Lifesaving liver transplantation for alcohol-associated liver disease continues to rise
Text Graphics
Dr. Jonathan G. Stine- Lifesaving liver transplantation for alcohol-associated liver disease continues to rise
From:
Dr. Jonathan G. Stine, MD MSc, FACP Dr. Jonathan G. Stine, MD MSc, FACP
Hershey, PA
Tuesday, March 3, 2020


Dr. Jonathan G. Stine, MD MSc, FACP
 

Dr. Jonathan G. Stine- Lifesaving liver transplantation for alcohol-associated liver disease continues to rise

The incidence of advanced alcohol-associated liver disease is rising in the United States. In spite of sparse best clinical practice guidance, rates of liver transplantation for alcohol associated hepatitis are also increasing.  Published this week by Digestive Diseases and Sciences, Drs. Jonathan G. Stine and Jessica L. Mellinger provide up-to-date commentary on the clinical controversy that surrounds liver transplantation for alcoholic hepatitis and review the findings of the recent Dallas Consensus Conference on Liver Transplantation for Alcohol Associated Hepatitis.

Link to Springer Medical Article:

Early Liver Transplantation for Severe Alcoholic Hepatitis

https://link.springer.com/article/10.1007%2Fs10620-020-06159-9

 



Here's a link to the full article. https://link.springer.com/epdf/10.1007/s10620-020-06159-9?author_access_token=8-iONyVqzwTrjnpitVJ-G_e4RwlQNchNByi7wbcMAY5vDd5ItNjl369pdsijLG9ollLg2vm6XkuSXufFgXQL00cLp5MBFRVXYzQVKb_SpeDWoVpOthRu1gI2DiTvyemuWk1VhZaaCCw_ahjQe4_I2Q%3D%3D

-------------------------------------------------------------------------------------------------------------

Personal profile

Research interests

Jonathan G. Stine, MD, MSc, FACP, is an Assistant Professor of Medicine and funded physician scientist in the Division of Gastroenterology and Hepatology at Penn State Health Milton S. Hershey Medical Center. Dr. Stine earned his undergraduate degree from Penn State.

Dr. Stine's clinical and research areas of expertise include NAFLD, coagulation disorders in chronic liver disease, drug-induced liver injury (DILI) and liver transplantation. The majority of his early work focused on DILI in both the population at large, as well as in special populations, including the elderly and patients with underlying chronic liver disease including cirrhosis. His more recent work has focused on liver transplantation coagulation disorders and outcomes-based research in which the link between pre- and post-transplantation vascular events was demonstrated. Additionally, Dr. Stine and his research group found that despite broader organ-sharing policies, geographic disparities persist and regional access to liver transplantation remains highly variable and inequitable.

Dr. Stine is the principal investigator on the NASHFit Trial and is continuing forward his work on the hypercoagulable environment in NASH patients, where he previously demonstrated that NASH increases one's risk of venous thromboembolic disease.

Dr. Stine serves as the Director of Research, Penn State Liver Center.

Professional information

Fellow of the American College of Physicians (FACP), 2016

Pickup Short URL to Share
News Media Interview Contact
Name: Dr. Jonathan G. Stine
Group: Pennsylvania State University Milton S. Hershey Medical Center
Dateline: Hershey, PA United States
Direct Phone: 717-531-1017
Jump To Dr. Jonathan G. Stine, MD MSc, FACP Jump To Dr. Jonathan G. Stine, MD MSc, FACP
Contact Click to Contact
Other experts on these topics